Tyra Biosciences(TYRA) - 2023 Q4 - Annual Results

Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 - - Strengthened balance sheet with approximately $200 million PIPE in Q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million - CARLS ...